RecruitingNot ApplicableNCT05539859

Efficacy and Safety of NeuroEndoscopic Surgery for IntraCerebral Hemorrhage

Efficacy and Safety of NeuroEndoscopic Surgery for IntraCerebral Hemorrhage: a Randomised, Controlled, Open-label, Blinded Endpoint Trial

Sponsor

Southwest Hospital, China

Enrollment

560 participants

Start Date

Nov 18, 2022

Study Type

INTERVENTIONAL

Conditions

Intracerebral Hemorrhage Basal Ganglia

Summary

To compare the efficacy and safety of neuroendoscopic hematoma removal and standard conservative treatment for patients with spontaneous supratentorial deep intracerebral hemorrhage.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Endoscopic surgery and Medical management for people with intracerebral hemorrhage basal ganglia. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREEndoscopic surgery

Subjects will receive surgical hematoma evacuation using neuroendoscope, followed by medical management

OTHERMedical management

Subjects will initially receive the standard medical therapies for the treatment of intracerebral hemorrhage, according to the latest available guideline.